(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.
Werewolf Therapeutics's earnings in 2026 is -$56,265,000.On average, 6 Wall Street analysts forecast HOWL's earnings for 2026 to be -$47,751,232, with the lowest HOWL earnings forecast at -$60,483,598, and the highest HOWL earnings forecast at -$37,249,460. On average, 4 Wall Street analysts forecast HOWL's earnings for 2027 to be -$79,062,162, with the lowest HOWL earnings forecast at -$104,774,737, and the highest HOWL earnings forecast at -$50,516,391.
In 2028, HOWL is forecast to generate -$72,866,067 in earnings, with the lowest earnings forecast at -$97,631,005 and the highest earnings forecast at -$45,413,725.